# Eckert & Ziegler to supply Lutetium-177 to Alpha-9 Theranostics for clinical trials

Eckert & Ziegler has signed a clinical supply agreement with Alpha-9 Theranostics to supply its medical radioisotope Lutetium-177 (n.c.a. 177Lu) for the clinical development of Alpha-9's investigational drugs for solid and hematologic malignancies.

- Type: Contract
- Announced: 2022-03-23
- Status: completed
- Products: Lutetium-177 (n.c.a. 177Lu) radioisotope
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Eckert & Ziegler](https://endata.com/companies/41023.md) (supplier)
- [Alpha-9 Theranostics](https://endata.com/companies/61816.md) (customer)

## Sources

- [a9oncology.com](https://www.a9oncology.com/eckert-ziegler-to-supply-canadian-alpha-9-theranostics-with-lutetium-177-for-clinical-trials/), 2022-03-23: "Eckert & Ziegler (ISIN DE0005659700, TecDAX) has executed with the Canadian biotech company Alpha-9 Theranostics Inc. (Alpha-9) a clinical supply agreement for Eckert & Ziegler’s medical radioisotope Lutetium-177 (non-carrier-added 177Lu)."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.